Tanco Kimberson, Olson Amanda, Fellman Bryan, Jankowski Mika, Lai Stephen Y, Shete Sanjay, Harbison Kevin, Scheid Jennifer, Bruera Eduardo
Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Palliat Med. 2023 Nov;26(11):1482-1487. doi: 10.1089/jpm.2023.0075. Epub 2023 Jun 6.
To understand real-world dispensing and utilization patterns of medical cannabis (MC) and its financial impact on patients, we analyzed the database of a cannabis company licensed in New York state. To evaluate the tetrahydrocannabinol (THC)/cannabidiol (CBD) dose ratios, association of various medical conditions to THC/CBD dose, and the cost of products in registered patients receiving MC from four licensed state dispensaries. Retrospective analysis conducted on anonymized data between January 1, 2016 and December 31, 2020 listing 422,201 dispensed products from 32,845 individuals aged 18 years and older. Adult patients with medical certification for cannabis use in New York, USA. The database included patient's age, gender, qualifying medical condition, type and dose of product, medication directions, and amount of product dispensed. Findings showed a median age of 53 years with 52% of patients female. Males were found to use more products than females (1.06:1). Pain (85%) was the most common medical condition and inhalation (57%) the most common route except when used for cancer-directed treatment and neurological conditions. Individuals received a median of six prescriptions costing a median of $50/product. Average THC:CBD ratios were 28:0.5 mg/day and 12:0.25 mg/dose. Neurological conditions demonstrated the highest average cost [mean (95% confidence interval {CI}): $73 ($71-$75)] and average CBD/dose per product [mean (95% CI): 5.89 (5.38-6.40)]. Individuals with a history of substance use disorder utilizing MC as an alternative substance displayed the highest average THC/dose [mean (95% CI): 14.25 (13.36-15.14)]. MC was utilized for various medical conditions with variability in THC:CBD ratio seen depending on the condition. Cost variation was also observed based on the individual's medical condition.
为了解医用大麻（MC）在现实世界中的配药和使用模式及其对患者的经济影响，我们分析了一家在纽约州获得许可的大麻公司的数据库。评估四氢大麻酚（THC）/大麻二酚（CBD）剂量比、各种医疗状况与THC/CBD剂量的关联，以及从四家获得许可的州药房接受MC的注册患者的产品成本。对2016年1月1日至2020年12月31日期间的匿名数据进行回顾性分析，列出了来自32845名18岁及以上个体的422201种配药产品。美国纽约有医用大麻使用医学认证的成年患者。该数据库包括患者的年龄、性别、符合条件的医疗状况、产品类型和剂量、用药说明以及配药产品数量。研究结果显示，患者的中位年龄为53岁，52%为女性。发现男性使用的产品比女性多（1.06:1）。疼痛（85%）是最常见的医疗状况，吸入（57%）是最常见的给药途径，用于癌症定向治疗和神经疾病时除外。个体接受的处方中位数为6张，产品中位数成本为50美元/件。平均THC:CBD比率为28:0.5毫克/天和12:0.25毫克/剂。神经疾病的平均成本最高[平均值（95%置信区间{CI}）：73美元（71-75美元）]，每种产品的平均CBD/剂量最高[平均值（95%CI）：5.89（5.38-6.40）]。有物质使用障碍病史并将MC用作替代物质的个体显示出最高的平均THC/剂量[平均值（95%CI）：14.25（13.36-15.14）]。MC被用于各种医疗状况，根据状况不同，THC:CBD比率也有所不同。根据个体的医疗状况也观察到了成本差异。
